One-Shot hope for kids with Muscle-Wasting disease after other drugs fail

NCT ID NCT05386680

Summary

This study tested a single spinal injection of a gene therapy called OAV101 in children and teens (ages 2 to 18) with spinal muscular atrophy (SMA) who had previously stopped other SMA treatments. The main goal was to see if the one-time treatment was safe and well-tolerated. Researchers also checked if it helped improve or maintain the children's motor skills and upper body strength over one year.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SPINAL MUSCULAR ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boston Childrens Hospital

    Boston, Massachusetts, 02215, United States

  • Child Hosp Of The Kings Daughters

    Norfolk, Virginia, 23507, United States

  • Novartis Investigative Site

    Parkville, Victoria, 3052, Australia

  • Novartis Investigative Site

    Leuven, 3000, Belgium

  • Novartis Investigative Site

    Montreal, Quebec, H4A 3J1, Canada

  • Novartis Investigative Site

    Bron, 69677, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Roma, RM, 00168, Italy

  • Novartis Investigative Site

    Kurume, Fukuoka, 830-0011, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 162 8666, Japan

  • Novartis Investigative Site

    Utrecht, 3584, Netherlands

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

  • University of Wisconsin Madison Medical School

    Madison, Wisconsin, 53792-7375, United States

Conditions

Explore the condition pages connected to this study.